Human Molecular Genetics
-
The Group for Human Molecular Genetics is dedicated to in vitro disease modeling. The main research topics of the Group are:
Modeling brain diseases - Within this topic, we study the molecular mechanisms underlying neurodevelopmental disorders, neurodegenerative diseases, traumatic brain injuries, cerebral ischemia, and brain tumors. To study the molecular mechanisms, we mastered the reprogramming of somatic cells into pluripotent stem cells, the formation of brain organoids, the modulation of selected genes and miRNAs expression in human cells, and the sequencing of RNA, whole genomes, and exomes.
Modeling of malignant diseases - To study the malignant phenotype of different types of tumors and the role of the tumor microenvironment, we develop 3D mono- and co-culture models. We apply OMICS analysis to identify the molecular mechanisms underlying the pathophysiology of cancer, their complexity, and heterogeneity, as well as for the detailed characterization of complex model systems used in in vitro studies. Also, we study the anti-tumor potential of natural and synthetic compounds and elucidate their mechanisms of action. In our research, we apply in vitro assays on many permanent cell lines originating from different types of tumors or normal tissues and in vivo assays using zebrafish as a model.
The Group for Human Molecular Genetics offers:
Analysis of the DNA fragmentation level of spermatozoa as an addition to existing protocols in the treatments of male sterility.
-
Danijela Drakulic, Full Research Professor
E-mail: danijela.drakulic@imgge.bg.ac.rs
Tel: +381 65 3976212
Vojvode Stepe 444a, 11042 Belgrade 152, Serbia -
FULL RESEARCH PROFESSOR
ASSOCIATE RESEARCH PROFESSOR
ASSISTANT RESEARCH PROFESSOR
RESEARCH ASSISTANT
JUNIOR RESEARCHERS
IMGGE work program for 2024 - Ministry of Science, Technological Development and Innovation of the Republic of Serbia, 451-03-66/2024-03/200042, 2024
Strengthening regional stem cells based research for advancement of multi modal innovative strategy for modelling neurodevelopmental disorders (STREAMLINE) (2022-2025)
